Oana Săndulescu, Mădălina Irimia, Otilia Elisabeta Benea, Mariana Mărdărescu, Liliana Lucia Preoțescu, Carmen Mihaela Dorobăț, Isabela Ioana Loghin, Irina Cristina Nicolau, Raluca Elena Jipa, Ramona Ștefania Popescu, Cristina Loredana Benea, Alina Cozma, Ioana Andreea Dărămuș, Victor Daniel Miron, Liviu Jany Prisăcariu, Adriana Florina Bahnă, Irina Nistor, Oana Manuela Secrieru, Silvas George, Andreea Bîrcă, Loredana Dobrea, Alexandra-Ștefana Șogorescu, Ioana Viziteu, Anca Streinu-Cercel
Introduction: Development of highly active antiretroviral therapy marked an important step forward in the management of people living with HIV and fixed dose combinations are now available to be used as modern antiretroviral regimens. The single-tablet regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) was recently approved in Europe and included in international guidelines and recommendations. It became available in Romania in early 2021. We present the real-world results from a retrospective analysis of patients initiating BIC/FTC/TAF in two HIV centers in Romania...
December 2021: Germs